Replies to post #148092 on Anavex Life Sciences Corp (AVXL)

[Investor2014]

Thanks!

Was it a presentation put together especially for the ASM?

Cause P.51 in the March 2018 corporate presentation is not dose/response correlation.

Will be very interesting to eventually see the actual inclusion/exclusion criteria.

[LakeshoreLeo1953]

Well down the road for trial start, but....

The issue will be HOW selective the enrollment becomes.

Not trying to characterize a magic bullet required to
be successful, but there certainly is a trial characteristic
that becomes almost Orphan in design. That I believe
seriously alters future valuation.